title: Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
abstract: Multikinase inhibitors have become first-line agents for treatment of multiple systemic cancers. These agents are very effective but can also cause a variety of toxicities affecting the skin, hair, and nails. One of the most common reactions is the hand-foot skin reaction, distinct from hand-foot syndrome caused by more traditional chemotherapy agents. All of these cutaneous reactions can negatively affect patients' quality of life and can lead to dose modifications and treatment interruptions. This article reviews the cutaneous toxicities from sorafenib and sunitinib with emphasis on treatment strategies.
authors.affiliation: Department of Dermatology, Henry Ford Health System, Detroit, Michigan, USA. beth.mclellan@nyumc.org
authors.forename: Beth
authors.initials: B
authors.lastname: McLellan
authors.forename: Holly
authors.initials: H
authors.lastname: Kerr
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005533:Foot Dermatoses / Q000139:chemically induced / Q000473:pathology; D006229:Hand Dermatoses / Q000139:chemically induced / Q000473:pathology; D060831:Hand-Foot Syndrome / Q000209:etiology / Q000473:pathology; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D011788:Quality of Life; D000077157:Sorafenib; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib